ATXN2L and migraine disorder: Several treatments were predictive of pain improvement in the migraine-like group, including oral α2δ ligands (OR = 2.74, 95%CI 2.73–2.96, p = 0.02), muscle relaxants (OR = 1.36, 95%CI 1.33–1.37, p < 0.005), and TNS (OR = 1.20, 95%CI 1.19–1.21, p < 0.005).